REZOLV3R is a randomised, double-blind, multi-centre trial treating symptomatic patients with recurrent malignant ascites suitable for paracentesis and a paracentesis-free interval of 28 days or less. The aim of the study is to determine if intraperitoneal bevacizumab following paracentesis, compared to control, will increase the time between required therapeutic drainage of malignant ascites, and if this will improve quality of life and optimise management of these patients in the final months of life.
